Active Ingredient History

NOW
  • Now
Lonaprisan is a synthetic, steroidal antiprogestogen which was under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis, dysmenorrhea, and breast cancer but was discontinued. It is a potent and highly selective silent antagonist of the progesterone receptor (PR). The drug reached phase II clinical trials prior to its discontinuation.   Wikipedia

  • SMILES: CC(=O)c1ccc(cc1)[C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C(F)(F)C(F)(F)F)[C@@H]4CCC5=CC(=O)CCC5=C24
  • InChIKey: VHZPUDNSVGRVMB-RXDLHWJPSA-N
  • Mol. Mass: 508.53
  • ALogP: 6.72
  • ChEMBL Molecule:
More Chemistry
11-(4-acetylphenyl)-17-hydroxy-17-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one | bay86-5044 | lonaprisan | zk230211 | zk 230211 | zk-230211

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue